Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study-Reference-Cited by-同舟云学术

Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study

Published:2008-11 Issue:5 Volume:54 Page:1089-1096
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Di Lorenzo Giuseppe,Figg William D.,Fossa Sophie D.,Mirone Vincenzo,Autorino Riccardo,Longo Nicola,Imbimbo Ciro,Perdonà Sisto,Giordano Antonio,Giuliano Mario,Labianca Roberto,De Placido Sabino

Publisher

Elsevier BV

Subject

Urology

Reference15 articles.

1. Cancer statistics 2007;Jamal;CA Cancer J Clin,2007

2. Hormone refractory prostate cancer. Where are we going?;Di Lorenzo;Drugs,2007

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

4. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

5. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies;Gerber;Cancer Res,2005

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 4-Nerolidylcatechol (4-NC) and Docetaxel Synergize in Controlling Androgen- independent Prostate Cancer Cells;Current Topics in Medicinal Chemistry;2023-04

2. Nimbolide enhances the antitumor effect of docetaxel via abrogation of the NF-κB signaling pathway in prostate cancer preclinical models;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2022-12

3. Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials;Cureus;2022-03-07

4. Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets;International Journal of Molecular Sciences;2021-09-14

5. Current research progress in targeted anti‐angiogenesis therapy for osteosarcoma;Cell Proliferation;2021-07-26